SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

BACKGROUND: Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cardiovasc Diabetol
Egile Nagusiak: Li, Chenguang, Zhang, Jie, Xue, Mei, Li, Xiaoyu, Han, Fei, Liu, Xiangyang, Xu, Linxin, Lu, Yunhong, Cheng, Ying, Li, Ting, Yu, Xiaochen, Sun, Bei, Chen, Liming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6359811/
https://ncbi.nlm.nih.gov/pubmed/30710997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0816-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak